Stifel analyst Alex Thompson raised the firm’s price target on Argenx (ARGX) to $882 from $797 and keeps a Buy rating on the shares. The firm the company’s model to reflect confidence in its pipeline following the recent positive topline data in seronegative myasthenia gravis. In addition, Argenx has multiple Phase 3 readouts for efgartimod over the next 12-24 months, the analyst tells investors in a research note. Stifel likes the share setup over the next 12 months.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARGX:
- Argenx Completes Phase 1 Study on ARGX-109: Key Insights for Investors
- Argenx’s Strategic Diversification and Promising Pipeline Highlighted by Buy Rating
- Argenx assumed with a Buy at Truist
- Argenx downgraded to Hold from Buy at Deutsche Bank
- Deutsche Bank downgrades Argenx to Hold after greater than 40% rally